Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma

OBJECTIVE: Multiple therapeutic agents exist for advanced hepatocellular carcinoma (HCC), but prognostic factors in second-line and subsequent therapies are unclear. Ramucirumab is a molecular-targeted agent effective against hepatocytes with alpha-fetoprotein (AFP) >400 ng/mL after sorafenib fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Rie, Motomura, Kenta, Ooho, Aritsune, Aratake, Yoshifusa, Ueda, Akihiro, Senju, Takeshi, Tanaka, Yuki, Yada, Masayoshi, Tanaka, Kohsuke, Kuwano, Akifumi, Morita, Yuusuke, Nagasawa, Shigehiro, Ooe, Mari, Mutsuki, Taiji, Yoshimoto, Tsuyoshi, Yamashita, Naoki, Nakashima, Mai, Hioki, Tomonobu, Koyanagi, Toshimasa, Higuchi, Nobito, Nakamura, Tsukasa, Harada, Shigeru, Tanaka, Masatake, Tada, Seiya, Satoh, Takeaki, Uchimura, Koutarou, Kuniyoshi, Masami, Nakamuta, Makoto, Kohjima, Motoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683807/
https://www.ncbi.nlm.nih.gov/pubmed/36328582
http://dx.doi.org/10.2169/internalmedicine.9237-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683807/
https://www.ncbi.nlm.nih.gov/pubmed/36328582
http://dx.doi.org/10.2169/internalmedicine.9237-21

Ejemplares similares